Cannabis for Tourette Syndrome: What a New Meta-Analysis Really Shows

CED Clinical Relevance

Tourette syndrome (TS) is a neurodevelopmental condition marked by involuntary motor and vocal tics, often accompanied by obsessive-compulsive disorder (OCD) and attention-deficit/hyperactivity disorder (ADHD). Standard pharmacologic options, including antipsychotics and alpha-2 agonists, frequently carry meaningful side-effect burdens (sedation, weight gain, metabolic changes, extrapyramidal symptoms), and many patients discontinue treatment because of them. That gap is exactly why a new meta-analysis on cannabis-based medicines (CBMs) for tic control is worth a careful look, not a headline-driven one.

Study Snapshot

A systematic review and meta-analysis published in the journal Neuroscience examined whether cannabis-based medicines reduce tic severity in adults with Tourette syndrome.

• Citation: Mann GS, Gadelmawla AF, Dway A, et al. Cannabis for tic control: a systematic review and meta-analysis of its efficacy in Tourette syndrome management. Neuroscience. 2026 Jun 1;609:137-145.
• DOI: 10.1016/j.neuroscience.2026.05.044
• PMID: 42229830
• Registration: PROSPERO CRD420251088633
• Search strategy: PubMed, Google Scholar, ScienceDirect, and the Cochrane Collaboration Database, searched through July 2, 2025
• Screening: 1,105 articles screened; 8 studies (a mix of cohort studies and randomized controlled trials) met inclusion criteria for the review; 7 of those were pooled in the meta-analysis
• Population: 306 adult patients with Tourette syndrome
• Outcome measures: Yale Global Tic Severity Scale (YGTSS) and Premonitory Urge for Tics Scale (PUTS), compared pre- versus post-treatment
• Results: YGTSS scores dropped by a mean difference of 13.29 points (95% CI, -21.67 to -4.91; P = 0.002). PUTS scores dropped by a mean difference of 4.09 points (95% CI, -7.24 to -0.93; P = 0.01)

How Strong Is This Evidence?

This is a systematic review and meta-analysis, which sits higher on the evidence hierarchy than any single trial. The authors pre-registered their protocol with PROSPERO, which is a good methodological sign. That said, three things temper how much weight this evidence should carry right now.

First, the pooled population is modest at 306 patients across seven studies, and the included studies are a mix of cohort designs and randomized controlled trials rather than a uniform set of placebo-controlled RCTs. Second, the analysis compares pre-treatment to post-treatment scores within groups. That design cannot fully separate a true drug effect from the natural waxing-and-waning course of tics, regression to the mean, or expectation effects, especially in the cohort studies. Third, the confidence intervals are wide, particularly for the PUTS outcome (-7.24 to -0.93), which signals real uncertainty about the true size of the effect even though the result is statistically significant.

The authors themselves are direct about this: “Larger, placebo-controlled trials are needed to confirm efficacy, ensure safety, and optimize dosing.” That is the correct read. This is a promising, hypothesis-generating signal, not a practice-changing result.

Where This Paper Deserves Skepticism

A few gaps are worth naming plainly, based on what is available in the published abstract and metadata:

• The abstract does not specify the cannabis-based medicine formulations, THC:CBD ratios, or dosing protocols used across the seven pooled studies, so it is not possible to say which product types or doses drove the result.
• The study population is adults only. Tourette syndrome is frequently diagnosed in childhood and adolescence, and this data says nothing about pediatric patients.
• No heterogeneity statistic (such as I-squared) or publication-bias assessment (such as a funnel plot or Egger’s test) is reported in the abstract, so the consistency of effect across the seven studies and the risk that negative studies went unpublished cannot be evaluated from this summary alone.
• Long-term safety data, drug interaction data, and cognitive or psychiatric outcome data (relevant given the high rates of comorbid OCD and ADHD in this population) are not part of this analysis.
• Mixing cohort studies with RCTs in a single pooled estimate can introduce bias that a purely randomized dataset would not have.

None of this means the finding is wrong. It means the finding is preliminary, and should be treated that way in clinical conversations.

What This Paper Does Not Show

This meta-analysis does not show that cannabis is superior to existing first-line therapies for tics, does not establish a standard dose or formulation, does not evaluate pediatric patients, and does not provide long-term safety data. It also does not compare cannabis-based medicine head-to-head against antipsychotics or behavioral therapy such as Comprehensive Behavioral Intervention for Tics (CBIT).

Dr. Caplan’s Take

I have followed the endocannabinoid system literature closely for two decades, and Tourette syndrome is one of the more interesting frontiers because the mechanistic rationale (endocannabinoid modulation of the motor circuits implicated in tic generation) has been discussed for years, while the clinical evidence has lagged behind. This meta-analysis does not close that gap, but it is a meaningful step: a PROSPERO-registered synthesis with a statistically significant signal across 306 patients is more than anecdote, and it is more than most of what this field has had to work with for TS specifically.

What I would tell a patient or family member asking about this today: this is a reason to bring cannabis-based options into a conversation with your treating clinician, particularly if standard therapies have caused intolerable side effects, not a reason to self-treat. Tourette syndrome has a genuinely difficult side-effect profile with existing pharmacotherapy, and a therapy class with a potentially more favorable tolerability profile deserves serious clinical attention. But “deserves attention” and “is proven” are different statements, and good medicine keeps those separate until the placebo-controlled trials the authors are calling for actually happen.

Frequently Asked Questions

What did this new study actually find about cannabis and Tourette syndrome?

A meta-analysis pooling data from 306 adults with Tourette syndrome across seven studies found that cannabis-based medicines were associated with statistically significant reductions in tic severity (YGTSS) and in the premonitory urge to tic (PUTS), compared with baseline.

How many patients and studies were involved?

Researchers screened 1,105 articles, included 8 studies (cohort studies and randomized controlled trials) in the systematic review, and pooled 7 of those studies, covering 306 adult patients, in the meta-analysis.

What is the YGTSS, and why does a 13-point drop matter?

The Yale Global Tic Severity Scale is the standard clinician-rated tool for measuring tic frequency, complexity, and impairment. A mean reduction of 13.29 points is a clinically meaningful change on this scale, though the wide confidence interval (-21.67 to -4.91) means the true average effect could be considerably smaller or larger than that point estimate.

Does this mean cannabis is now a recommended treatment for Tourette syndrome?

No. The study authors explicitly call for larger, placebo-controlled trials before efficacy, safety, and dosing can be confirmed. This is preliminary evidence, not a treatment guideline change.

Were these controlled clinical trials?

Not uniformly. The pooled studies were a mix of cohort studies and randomized controlled trials, analyzed using a pre-treatment versus post-treatment comparison rather than a single, consistent placebo-controlled design across all seven studies.

Does this research apply to children with Tourette syndrome?

No. The population studied was adult patients only. Tourette syndrome commonly begins in childhood, and this analysis does not address that population.

Why are researchers interested in cannabis for tics in the first place?

The endocannabinoid system is thought to play a role in modulating the motor circuits involved in tic generation, and existing first-line therapies (antipsychotics, alpha-2 agonists) often come with substantial side effects that limit long-term adherence, which creates interest in alternatives with potentially better tolerability.

Should someone with Tourette syndrome try cannabis based on this study?

Any decision like this should be made with a treating physician, not based on a single meta-analysis. This paper supports raising the topic in a clinical conversation, particularly if standard treatments have failed or caused intolerable side effects, but it does not support self-directed use.